Survodutide China Suppliers and Factory GLP1 Glucagon Dual Agonist

High-purity Survodutide 5MG and 10MG available from leading China suppliers. Our factory provides premium GLP-1 Glucagon dual agonists for metabolic research and liver fat reduction.

SupplierFuBai Peptidewww.glpfactory.com

View on supplier website More from this supplier

Source categories

Hot Products

About this product

Product information from the supplier.

Survodutide represents a breakthrough in metabolic pharmacology, developed through a strategic collaboration between Boehringer Ingelheim and Zealand Pharma. As a highly potent, once-weekly injectable, this investigational drug is engineered as a dual agonist, specifically targeting both Glucagon-Like Peptide-1 (GLP-1) and glucagon receptors to address complex metabolic dysfunctions.

By leveraging a synergistic mechanism of action, Survodutide does more than simply suppress appetite. It actively enhances the body's overall energy expenditure and facilitates the direct breakdown of hepatic lipids, providing a comprehensive approach to metabolic health and liver fat reduction that surpasses single-receptor agonists.

Detailed Parameters

Product Name	Survodutide	Drug Class	GLP-1 / Glucagon Dual Agonist
Administration	Subcutaneous Injection	Dosage Frequency	Once Weekly
Primary Targets	GLP-1 & Glucagon Receptors	Development Partners	Boehringer Ingelheim & Zealand Pharma
Main Application	Metabolic Disorder Research	Key Effect	Liver Fat Reduction
Mechanism	Dual Receptor Activation	Pharmacological Goal	Weight Loss & Energy Expenditure

Key Advantages

Dual-Action Synergy

Simultaneous activation of GLP-1 and glucagon receptors for superior metabolic control.

Weekly Administration

Optimized pharmacokinetic profile allowing for a convenient once-per-week dosing schedule.

Liver Fat Breakdown

Specifically engineered to directly reduce hepatic fat accumulation and improve liver health.

Energy Expenditure

Boosts basal metabolic rate to accelerate the body's natural energy consumption.

Appetite Regulation

Effective reduction of appetite through GLP-1 receptor modulation for weight management.

Advanced Engineering

Utilizes state-of-the-art peptide synthesis to ensure high purity and biological activity.

Product Gallery

Management Platforms

Cold Chain Logistics

Strict temperature-controlled shipping to maintain peptide stability and efficacy.

Quality Control

Rigorous HPLC and Mass Spec testing for every batch of genetic engineering peptides.

Regulatory Compliance

Adherence to global pharmaceutical manufacturing standards for biological products.

Batch Traceability

Full digital auditing from raw material sourcing to final product delivery.

Inventory Management

Real-time stock monitoring to ensure uninterrupted supply for research facilities.

Technical Support

Expert guidance on reconstitution and handling of biological drugs.

Investment Return Comparison

Metric	Single Agonist (Traditional)	Survodutide (Dual Agonist)
Metabolic Rate	Moderate Increase	Significant Boost
Liver Fat Impact	Indirect Reduction	Direct Breakdown
Satiety Level	High	Very High
Dosing Interval	Daily/Weekly	Weekly
Overall Efficacy	Standard	Enhanced Synergistic

Frequently Asked Questions

Q: What makes Survodutide different from standard GLP-1 peptides?

Unlike standard GLP-1 peptides, Survodutide is a dual agonist that targets both GLP-1 and glucagon receptors, allowing it to increase energy expenditure and break down liver fat more effectively.

Q: How is this product manufactured in the bio-pharmaceutical industry?

It is produced using advanced genetic engineering and peptide synthesis technologies, ensuring the precise sequence of amino acids required for dual-receptor activation.

Q: What is the primary benefit of glucagon receptor activation in this drug?

Glucagon receptor activation specifically helps in increasing energy expenditure and promoting the breakdown of fats in the liver, complementing the appetite suppression of GLP-1.

Q: Is Survodutide suitable for all types of metabolic research?

It is primarily designed for research focusing on obesity, Type 2 diabetes, and non-alcoholic steatohepatitis (NASH) due to its liver-targeting properties.

Q: What are the storage requirements for these biological products?

As a biological peptide, it typically requires strict cold-chain storage (usually 2-8°C or frozen) to prevent degradation and maintain biological activity.

Q: How does the once-weekly injection profile benefit the user?

The extended half-life reduces the frequency of administration, significantly improving patient compliance and maintaining stable plasma concentrations of the drug.